[Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)
date : 6/18/2024
The English version of the file has been published. (June 18, 2024)
Health and Global Policy Institute (HGPI) has offered policy recommendations and taken a number of other activities to promote patient and public involvement (PPI) in policy development process, under our stated mission of “Achieving citizen-centered health policy.” Recently, initiatives for PPI in processes of health policy development are now being advanced at both the national Government and local level at councils. However, new issues have been recognized consequently, which include lack of the diversities in and the number of individuals who desire to be involved. Based on our recognition of these issues, our PPI Support Project this fiscal year aims to promote the involvement of diverse patient and public representatives into policy development process.
Based on our discussions to date, we have compiled a ” Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government.” This guidance reviews how PPI in the policymaking process is important and outlines the initiatives that are required in the future to promote it. Please refer to the PDF file at the end of this document for the details of this guide.
FY2023 Advisory Board Members (Titles omitted; in Japanese alphabetical order by last name, absent members included)
Kyoko Ama (Representative, Children and Healthcare Project; Fellow, HGPI)
Shinsuke Amano (Chair, The Japan Federation of Cancer Patient Groups; CEO, Group Nexus Japan)
Etsuko Aruga (Professor, Department of Palliative Medicine, Teikyo University School of Medicine)
Naomi Sakurai (President, Cancer Solutions Co., Ltd)
Takeshi Shukunobe (President and CEO, PPeCC)
Kazuyuki Suzuki (Senior Lead, Patient Engagement Group, Strategy & Execution, Novartis Pharma K.K.)
Yasuhiro Sensho (CEO, SENSHO-GUMI, Co., Ltd.; Former Director-General, MHLW)
Teppei Maeda (Lawyer, Maeda & Unosawa Law Offices; Representative, Medical Basic Act Community)
Kaori Muto (Professor, Department of Public Policy Studies, Institute of Medical Science, University of Tokyo)
Akira Morita (Representative Director, Next Generation Fundamental Policy Research Institute (NFI))
Ikuko Yamaguchi (Chief Director, Consumer Organization for Medicine and Law (COML))
Risa Yamazaki (Public Affairs Group, External Affairs Department, Chugai Pharmaceutical Co., LTD.)
Project sponsors (in Japanese alphabetical order)
National Graduate Institute for Policy Studies (GRIPS) Global Health Innovation Policy Program
Syneos Health Commercial K.K.
Chugai Pharmaceutical Co., Ltd.
Novartis Pharma K.K.
Guidance/brochure
Guidance | Brochure | |
For Web | For Print Please print in landscape orientation, double-sided (short edge binding), and fold in half. |
|
Top Research & Recommendations Posts
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [New Report] Policy Priorities for Super-Ageing Japan: Health Innovation and Economic Growth in the COVID-19 Pandemic Era (February 24, 2021)
- [Report and Recommendations] Discussion Points in Healthcare DX Project Expert Panel Meeting (April 2, 2024)
- [Policy Recommendations] Achieving Equity in Multidisciplinary Pain Treatment and Support Systems for Pain Management (March 31, 2023)
Featured Posts
-
2024-10-07
[Registration Open] Planetary Health Expert Meeting “Building the Future of Healthcare: A Vision for Sustainable and Resilient Health Systems with GGHH” (November 5, 2024)
-
2024-10-28
[Registration Open] (Hybrid Format) Public Symposium “Promoting CVD Control Based on the Needs of People Living with or Affected by Cardiovascular Diseases: Towards Effective Implementation of the Second Phase CVD Control Plans” (November 22, 2024)
-
2024-10-30
[Event Report] Advisory Board Meeting for Meaningful Involvement Promotion Project “Promoting People with Lived Experience Participation in Policy-Making: Building a Social Foundation for Proactive Engagement” (September 11, 2024)
-
2024-10-31
[HGPI Policy Column] (No.49) From the Mental Health Project ”Changes in the Japanese Mental Health Policy and Future Policy Topics” (The 2nd part ”Issues surrounding long-term hospitalization and future policy topics”)
-
2024-11-01
[Registration Open] Designing for Dementia Briefing Session 2024 – Conversations on the Trajectory of Our Activities and Envisioning the Future (December 3, 2024)